Abstract Number: 2753 • 2018 ACR/ARHP Annual Meeting
Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with a predisposition for the cranial branches of the external carotid artery. However, aorta and…Abstract Number: 2754 • 2018 ACR/ARHP Annual Meeting
Comparison between Tocilizumab Prescribed As Monotherapy Versus Combined with Conventional Immunosuppressant Agents in Giant Cell Arteritis Patients
Background/Purpose: Giant cell arteritis (GCA) can be refractory to corticosteroid therapy (1-3). Tocilizumab (TCZ) has been approved in the treatment of GCA. There are no…Abstract Number: 2755 • 2018 ACR/ARHP Annual Meeting
Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with a special predilection for extracranial branches of the external carotid artery. Among its most…Abstract Number: 2756 • 2018 ACR/ARHP Annual Meeting
A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…Abstract Number: 2757 • 2018 ACR/ARHP Annual Meeting
A Comparison of Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing
Background/Purpose: Tocilizumab (TCZ), an anti–interleukin-6 receptor (IL-6R) monoclonal antibody, was recently approved for the treatment of patients with giant cell arteritis (GCA) based on results…Abstract Number: 2758 • 2018 ACR/ARHP Annual Meeting
Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study
Background/Purpose: The efficacy of tocilizumab (TCZ), an anti-IL-6 targeted monoclonal antibody, in patients with refractory GCA has been demonstrated. The purpose of this study was…Abstract Number: 2759 • 2018 ACR/ARHP Annual Meeting
Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis
Background/Purpose: Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serologic (ESR, CRP) parameters. Imaging assessment, including 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET),…Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…Abstract Number: 2761 • 2018 ACR/ARHP Annual Meeting
High-Dose Prednisone Use up to 42 Days Prior to Temporal Artery Biopsy (TAB) Did Not Reduce Yield of Positive Biopsy in the Veterans Health Administration (VHA) Database Cohort
Background/Purpose: Temporal artery biopsy (TAB) currently remains the gold-standard confirmatory test for the diagnosis of giant cell arteritis (GCA); positive TAB justifies long-term steroid use…Abstract Number: 2762 • 2018 ACR/ARHP Annual Meeting
A Longer or Bilateral Temporal Artery Biopsy (TAB) Is More Likely to Yield a Positive Result for Giant Cell Arteritis (GCA) in the Veterans Health Administration (VHA) Database Cohort
Background/Purpose: TAB is currently considered the gold standard for the diagnosis of GCA. However, it is suspected that the sensitivity of TAB is limited by…Abstract Number: 2763 • 2018 ACR/ARHP Annual Meeting
Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis
Background/Purpose: To investigate the utility of serum free light chains (FLC), antiphospholipid antibodies (APL), and cytokines in the evaluation of patients with biopsy-proven giant cell…Abstract Number: 2764 • 2018 ACR/ARHP Annual Meeting
Incidence, Characteristics and Management of Giant Cell Arteritis in France: A Study Based on National Health Insurance Claims Data
Background/Purpose: Giant cell arteritis (GCA) is an immune-mediated, primary systemic vasculitis that affects large and medium-sized arteries. GCA may cause vision loss in up to…Abstract Number: 2765 • 2018 ACR/ARHP Annual Meeting
Thyroid Artery Involvement Detected By Colour-Doppler Ultrasonography in an Incipient, Single Centre Giant Cell Arteritis Cohort
Background/Purpose: The inflammation of thyroid arteries (ThA) is not commonly considered and investigated in giant cell arteritis (GCA). We aimed to estimate the frequency of…Abstract Number: 2766 • 2018 ACR/ARHP Annual Meeting
Seasonal Variation in Incidence of Giant Cell Arteritis: A Population-Based Cohort Study
Background/Purpose: To determine whether there is a seasonal peak onset of giant cell arteritis (GCA). We examined the seasonal variability of GCA in a geographically-defined…Abstract Number: 2767 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster As a Risk Factor for Polymyalgia Rheumatica: A Population-Based Study
Background/Purpose: The presence of varicella zoster virus (VZV) signal in the temporal arteries of patients with giant cell arteritis has suggested a possible role of…
ACR Meeting Abstracts